• Long Zhang, Yumiao Zhao, Junli Jia, Lisha Huang, Weili Chu, Qinfu Xu, Yanbing Sheng, and Aiguo Xu.
• Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
• Medicine (Baltimore). 2021 Jun 25; 100 (25): e25672e25672.

BackgroundThe goal of the present study is to evaluate the efficacy and safety of Bailing capsules, which is a traditional Chinese drug that can improve lung functionality when used to treat chronic obstructive pulmonary disease (COPD) patients.MethodsA comprehensive search will be performed on the following primary electronic databases: PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, and WanFang database. A search of secondary sources includes reference lists of included studies. Two pairs of review authors will screen and scrutinize selected articles. This study will analyze continuous data as mean differences and dichotomous data as odds ratios, both with 95% confidence intervals. A sensitivity analysis will also be conducted to evaluate the stableness of the outcomes. RevMan 5.3 software was adopted to accomplish all the statistical analysis.ResultsThe results obtained in this research shall be published in a peer-reviewed journal.ConclusionBased on the interpretations of the results, useful conclusions will be presented. These conclusions will offer additional insights with useful evidence to assess whether it is viable to use Bailing capsules as an effective and safety treatment option for COPD.Ethics And DisseminationThe present work does not involve any humans or animals; therefore, ethical approval is not needed.Systematic Review RegistrationMarch 26, 2021.osf.io/kvgbu. (https://osf.io/kvgbu/).Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…